These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 15975377)
1. Invited commentary. Hiramatsu Y Ann Thorac Surg; 2005 Jul; 80(1):257-8. PubMed ID: 15975377 [No Abstract] [Full Text] [Related]
2. Platelet preservation with a glycoprotein IIb/IIIa inhibitor in a porcine cardiopulmonary bypass model. Kondo N; Suzuki Y; Wakayama F; Tamai Y; Ji K; Fukui K; Fukuda I Ann Thorac Surg; 2005 Jul; 80(1):251-7. PubMed ID: 15975376 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass. Tabata S; Yamaguchi S; Nagamine H; Tomita S; Arai S; Takemura H; Watanabe G Eur J Cardiothorac Surg; 2004 Aug; 26(2):289-93. PubMed ID: 15296885 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies. Ahrens I; Peter K Thromb Haemost; 2008 May; 99(5):803-4. PubMed ID: 18449408 [No Abstract] [Full Text] [Related]
5. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439 [TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation. Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411 [TBL] [Abstract][Full Text] [Related]
7. Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia. Straub A; Schiebold D; Wendel HP; Azevedo R; Dietz K; Ziemer G Thromb Res; 2008; 122(3):383-9. PubMed ID: 18304613 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological approaches to studying platelet function: an overview. Hourani SM Methods Mol Biol; 2004; 273():73-86. PubMed ID: 15308794 [No Abstract] [Full Text] [Related]
9. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? Aukrust P; Damas JK; Solum NO J Am Coll Cardiol; 2004 Jun; 43(12):2326-8. PubMed ID: 15193701 [No Abstract] [Full Text] [Related]
10. Platelet activation and progression to complications. Kereiakes DJ; Michelson AD Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126 [TBL] [Abstract][Full Text] [Related]
11. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. Mousa SA; Ahmad S Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513 [TBL] [Abstract][Full Text] [Related]
12. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. Madsen NJ; Holmes CE; Serrano FA; Sobel BE; Schneider DJ Am J Cardiol; 2007 Aug; 100(4):722-7. PubMed ID: 17697836 [TBL] [Abstract][Full Text] [Related]
13. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions]. Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720 [No Abstract] [Full Text] [Related]
15. Platelet function in clopidogrel-treated patients with acute coronary syndrome. Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574 [TBL] [Abstract][Full Text] [Related]
16. GP IIb/IIIa blockade during peripheral artery interventions. Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207 [TBL] [Abstract][Full Text] [Related]
17. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Bassler N; Loeffler C; Mangin P; Yuan Y; Schwarz M; Hagemeyer CE; Eisenhardt SU; Ahrens I; Bode C; Jackson SP; Peter K Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):e9-15. PubMed ID: 17170374 [TBL] [Abstract][Full Text] [Related]
18. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Gurbel PA Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887 [TBL] [Abstract][Full Text] [Related]
19. Platelet function testing and implications for clinical practice. Collet JP; Montalescot G J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130 [TBL] [Abstract][Full Text] [Related]
20. Platelet protective effect of TAK-029, a novel glycoprotein IIb/IIIa antagonist: an in vitro study. Kawahito K; Fujimura A; Kobayashi E; Misawa Y; Fuse K Artif Organs; 1998 Apr; 22(4):348-52. PubMed ID: 9555968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]